MANAGEMENT TEAM
Mr. Winter Huang, Chairman of the Board of
Directors
Mr. Huang was originally trained and experienced petrochemist, and later
shifted his focus to natural drug development in the late 1980's. Mr.
Huang was the key person in the development of the CARESENG® series.
He brings his expertise in phytochemicals and significant entrepreneurship
with many years of experience in a variety of business fields. The laboratory
he established has been providing novel anti-cancer compounds and developed
a proprietary process that reduces material cost to an economic level
feasible for mass production.
Dr. William Jia, Ph.D., CSO, Associate Professor-UBC;
Senior Scientist-BC Cancer Research Center; Canadian Institute of Health
Research (CIHR) Scholar.
Dr. Jia has been a researcher at UBC since 1987,
and a senior scientist in medical oncology at the BC Cancer Agency since
1994. He is the inventor of PAN-11 induced MACE, with 2 patents applied
for, and is the recipient of numerous competitive Medical Research Council
of Canada (now CIHR) and National Cancer Institute of Canada research
grants, as well as grants from other sources. He has 31 publications on
the brain and/or cancer. Dr. Jia leads the Company's research programs.
Dr. William Campbell, Ph.D., Senior Scientist,
CEO of PepMetric Technology Inc.
Dr. Campbell has over 30 year of experience
in the field of protein chemistry. In 1989, while in Japan as an associate
professor at Nagoya City University he discovered a novel enzyme, carboxypeptidase
R, an important regulator of inflammation and fibrinolysis. Over the past
several years he has made use of novel computer algorithms that create
peptide antibody mimetics to targets in proteins and has used peptide
array technology to identify potential drug candidates for both therapeutic
and diagnostic applications. After leaving Japan, Dr. Campbell spent two
years as visiting scientist at the Kinsmen Laboratory of Neurological
Research at the University of British Columbia before joining PepMetric.
Mr. James Cao, MBA, MSc, CFA, Chief Financial
Officer and General Manger
Mr. Cao has over 10 years of experience in
treasury, investment management, and accounting. Prior to joining Panagin,
James worked for UBC Sauder School of Business as a consultant and was
the Executive Manager of Investment Division of a large holding company
in Shanghai China, where he managed the whole investment portfolio.
SCIENTIFIC ADVISORY BOARD
Dr. James Goldie, MD, FRCPC
Dr. Goldie is
Clinical Emeritus Professor at University of British Columbia, former
Head of Medical Oncology of BC Cancer Agency. Dr. Goldie is a global leader
in oncology, especially in the field of drug resistant cancer treatment
and research. His theory (Goldie-Coldman Hypothesis) on cancer drug resistance
is quoted in almost all of today's major oncology textbooks. Dr. Goldie
has more than 200 peer-reviewed publications and 29 textbook or chapters
to his credit in the area of oncology. Dr. Goldie advises PanaGin on clinical
strategies and clinical trial protocol development.
Dr. Francis Law, Ph.D.
Dr. Francis Law is
currently a Professor in the Department of Biological Sciences at Simon
Fraser University. Dr. Francis Law's research interests include preclinical
and clinical studies on safety and efficacy of biopharmaceuticals, nutraceuticals
and natural health products especially Chinese herbal medicine; pharmacokinetic
studies using laboratory animals and humans; application of classical
and physiologically based pharmacokinetic(PBPK) models in herb research
and development; in vitro prediction of drug/herb interactions using human
liver microsomes and Caco-2 cells; analysis of active herbal components
using GC/MS and HPLC/MS/MS; registration submission to Health Canada and
US Food and Drug Administration for drugs and herbal products; environmental
risk assessment of new drug and herbal products; and GLP, GCP and GMP
compliance.
Dr. David Osoba, MD, FRCPC
Dr. David Osoba was a Professor of Medicine (Retired) at the University of British Columbia,
and former Vice-President of the British Columbia Cancer Agency. With
clinical background in medical oncology, Dr. David Osoba has research
experience in immunology, clinical trials and quality-of-life measurement.
For the past 17 years, he has been a member of the Quality of Life Committee
of the Clinical Trials Group of the National Cancer Institute of Canada
(Chair from 1986-1996) and a member of the Board of Directors and immediate
past president of the International Society for Quality of Life research
(ISOQOL). Also, he was an Associate Editor of Quality of Life Research
from its inception in 1992 until 2001. Dr. Osoba has more than 250 scientific
publications to his credit. Dr. Osoba advises Panagin on clinical trial
protocol development and data review.
Dr. Daniel Von Hoff, MD, FACP
Dr. Von Hoff is currently Professor of Medicine, Molecular and Cellular Biology and
Pathology, and Director of the Arizona Cancer Center at The University
of Arizona in Tucson. Dr. Von Hoff and his colleagues have been involved
in the development of numerous cancer agents, including gemcitabine, paclitaxel,
mitoxantrone, fludarabinedocetaxel, docetaxel, and CPT-11. Dr. Von Hoff
is the immediate past President of the American Association for Cancer
Research (AACR), past board member of the American Society of Clinical
Oncology (ASCO), a member of the FDA's Oncology Drug Advisory Committee
(ODAC), and a Fellow of the American College of Physicians. He is founder
and the Editor Emeritus of Investigational New Drugs - The Journal of
New Anticancer Agents; an Associate Editor of Clinical Cancer Research;
Co-Editor of Oncology Spectrums and is on the editorial board of Anti-cancer
Drugs and the International Journal of Oncology. Dr. Von Hoff has published
more than 470 papers, 120 book chapters, and more than 800 abstracts.
Dr. Daniel Von Hoff advises Panagin on late phase clinical trials.
MANUFACTURING ADVISOR
Mr. Milton Chen, Ph.D.(Biochemical Engineering)
B.Sc.(Chemical Engineering) Chemical expert
Mr. Milton Chen has been a chemical engineer with a cGMP manufacturer
of anticancer drugs in Canada since 1996. He is highly experienced in
process development, quality control and engineering of pharmaceutical
separation and purification processes at pilot and large scales.
